Literature DB >> 23681007

The most transformative drugs of the past 25 years: a survey of physicians.

Aaron S Kesselheim1, Jerry Avorn.   

Abstract

Strategic and legislative efforts to catalyse pharmaceutical innovation may be hampered by a lack of consensus over what characterizes an innovative drug. To help clarify this issue, we conducted an extensive survey on transformative drug development, involving ∼180 expert physicians based at 30 leading US academic medical centres, covering 15 medical specialties. In an iterative Delphi process, the survey participants narrowed a list of all new drugs approved in their fields in the past 25 years and reached consensus over those that they considered to be most transformative, which are presented in this article. Participants were also asked how various factors affected their opinion; they most often invoked the effectiveness and superiority of the drugs over existing alternatives when identifying transformative drug innovation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23681007     DOI: 10.1038/nrd3977

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  23 in total

1.  Defining rewardable innovation in drug therapy.

Authors:  Jeffrey K Aronson; Robin E Ferner; Dyfrig A Hughes
Journal:  Nat Rev Drug Discov       Date:  2012-03-30       Impact factor: 84.694

2.  Perestroika in pharma: evolution or revolution in drug development?

Authors:  Garret A FitzGerald
Journal:  Mt Sinai J Med       Date:  2010 Jul-Aug

3.  Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003.

Authors:  Domenico Motola; Fabrizio De Ponti; Pasqualino Rossi; Nello Martini; Nicola Montanaro
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

4.  Perspectives on the development of imatinib and the future of cancer research.

Authors:  Brian J Druker
Journal:  Nat Med       Date:  2009-10       Impact factor: 53.440

Review 5.  Lessons from 60 years of pharmaceutical innovation.

Authors:  Bernard Munos
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

Review 6.  The productivity crisis in pharmaceutical R&D.

Authors:  Fabio Pammolli; Laura Magazzini; Massimo Riccaboni
Journal:  Nat Rev Drug Discov       Date:  2011-06       Impact factor: 84.694

7.  New drugs and indications in 2010: inadequate assessment; patients at risk.

Authors: 
Journal:  Prescrire Int       Date:  2011-04

8.  The impact of incremental innovation in biopharmaceuticals: drug utilisation in original and supplemental indications.

Authors:  Ernst R Berndt; Iain M Cockburn; Karen A Grépin
Journal:  Pharmacoeconomics       Date:  2006-12       Impact factor: 4.981

9.  Physicians' views of the relative importance of thirty medical innovations.

Authors:  V R Fuchs; H C Sox
Journal:  Health Aff (Millwood)       Date:  2001 Sep-Oct       Impact factor: 6.301

10.  User fees and beyond--the FDA Safety and Innovation Act of 2012.

Authors:  Daniel B Kramer; Aaron S Kesselheim
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

View more
  7 in total

1.  A pain research agenda for the 21st century.

Authors:  Robert W Gereau; Kathleen A Sluka; William Maixner; Seddon R Savage; Theodore J Price; Beth B Murinson; Mark D Sullivan; Roger B Fillingim
Journal:  J Pain       Date:  2014-10-29       Impact factor: 5.820

Review 2.  Predictive validity in drug discovery: what it is, why it matters and how to improve it.

Authors:  Jack W Scannell; James Bosley; John A Hickman; Gerard R Dawson; Hubert Truebel; Guilherme S Ferreira; Duncan Richards; J Mark Treherne
Journal:  Nat Rev Drug Discov       Date:  2022-10-04       Impact factor: 112.288

3.  Integrated genome and tissue engineering enables screening of cancer vulnerabilities in physiologically relevant perfusable ex vivo cultures.

Authors:  Michael Hu; Xin Yi Lei; Jon D Larson; Melissa McAlonis; Kyle Ford; Daniella McDonald; Krystal Mach; Jessica M Rusert; Robert J Wechsler-Reya; Prashant Mali
Journal:  Biomaterials       Date:  2021-12-02       Impact factor: 15.304

4.  Mortality, Hospitalizations, and Expenditures for the Medicare Population Aged 65 Years or Older, 1999-2013.

Authors:  Harlan M Krumholz; Sudhakar V Nuti; Nicholas S Downing; Sharon-Lise T Normand; Yun Wang
Journal:  JAMA       Date:  2015-07-28       Impact factor: 56.272

5.  Identification of translational dermatology research priorities in the U.K.: results of an electronic Delphi exercise.

Authors:  S J Brown; S M Langan; S G Nicholls; K Shams; E Healy; N J Reynolds
Journal:  Br J Dermatol       Date:  2015-10-14       Impact factor: 9.302

6.  URGCP/URG4 promotes apoptotic resistance in bladder cancer cells by activating NF-κB signaling.

Authors:  Minglong Wu; Junxing Chen; Yuxi Wang; Jinqian Hu; Chang Liu; Chunxiang Feng; Xiaoyong Zeng
Journal:  Oncotarget       Date:  2015-10-13

7.  The Sanford Lorraine Cross Award for medical innovation: Advancing a rigorous and repeatable method for recognizing translational research leaders who today are bringing emerging transformative innovations to patients.

Authors:  Mitchell Horowitz; Joseph Simkins; David A Pearce
Journal:  J Clin Transl Res       Date:  2020-01-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.